IQVIA reported a strong Q1 2026 with record revenue, accelerating organic growth in both segments, and raised full-year EPS guidance. Management spent significant time explaining the low book-to-bill ratio was due to abnormally low pass-through bookings, not demand weakness, and highlighted AI as a tailwind for demand. Q1 revenue of $4.151B grew 8.4% reported / 6.0% constant currency, beating guidance.
IQVIA reported a strong Q1 2026 with record revenue, accelerating organic growth in both segments, and raised full-year EPS guidance. Management spent significant time explaining the low book-to-bill ratio was due to abnormally low pass-through bookings, not demand weakness, and highlighted AI as a tailwind for demand. Q1 revenue of $4.151B grew 8.4% reported / 6.0% constant currency, beating guidance.
Management expressed confidence in strong results, emphasized a clean quarter with accelerating growth, and dismissed concerns about bookings and AI disruptions, while pointing to record pipelines and positive demand indicators.
Q1 revenue of $4.151B grew 8.4% reported / 6.0% constant currency, beating guidance.
R&D Solutions net new bookings were $2.5B; low pass-throughs (one-third below historic average) artificially depressed the book-to-bill ratio to 1.04.
Management emphasized AI as a tailwind, with clients increasing demand for IQVIA's AI capabilities and the deployment of 192 agents across 64 use cases, noting 19 of top 20 pharma companies use IQVIA agents. They dismissed AI as a threat to bookings, noting zero trials lost to…
Management emphasized AI as a tailwind, with clients increasing demand for IQVIA's AI capabilities and the deployment of 192 agents across 64 use cases, noting 19 of top 20 pharma companies use IQVIA agents. They dismissed AI as a threat to bookings, noting zero trials lost to AI competitors, and highlighted new offerings like IQVIA.AI portal at NVIDIA GTC.
Backlog hits record $34.2B; next-12-month revenue up ~8%. Management expressed confidence in strong results, emphasized a clean quarter with accelerating growth, and dismissed concerns about bookings and AI disruptions, while pointing to record pipelines and positive demand indicators.
No specific capex discussion beyond mentioning capital expenditures of $127 million in Q1 and free cash flow of $491 million. No forward-looking capex or capacity investment commentary was provided.
Management expressed confidence in strong results, emphasized a clean quarter with accelerating growth, and dismissed concerns about bookings and AI disruptions, while pointing to record pipelines and positive demand indicators.
“The first quarter was, you know, pass-throughs was like about one-third lower than the historic average.”
“A large pharma client told us actually, if I can share that anecdote, that they plan to double the number of molecules in their pipeline because they are using AI to identify more targets”
| 지표 | 기간 | 범위 | 중간값 | 상태 |
|---|---|---|---|---|
| EPS | FY2026 | $12.65–$12.95 | $12.80 | RAISED |
| EPS | FY2026 Q2 | $2.98–$3.08 | $3.03 | GUIDED |
| Revenue | FY2026 | $17.15B–$17.35B | $17.25B | MAINTAINED |
| Revenue | FY2026 Q2 | $4.28B–$4.34B | $4.31B | GUIDED |
| 제시 시점 | 지표 | 목표 기간 | 가이던스 | 실제 | 결과 |
|---|---|---|---|---|---|
| FY2025 Q4 | Revenue | FY2026 Q1 | $4.15B–$4.5B | $4.151B | Met / beat |
Pfizer is expanding its commercial partnership with IQVIA, a sign of continued outsourcing and demand for IQVIA's services.
“Pfizer and IQVIA entered into a strategic regional promotion agreement covering selected Pfizer products across 23 countries in Europe.”
… markets and therapeutic areas using an AI-driven analytics platform. The engagement replaces hundreds of disconnected reports and dashboards from multiple vendors with a centralized managed AI-powered IQVIA insight solution. IQVIA secured a multi-year partnership with a mid-size client to provide a scalable AI-ready data foundation. The win demonstrates IQVIA's plug-and-play capabilities within a client's multi-provider technology ecosystem. Pfizer and IQVIA entered into a strategic regional promotion agreement covering selected Pfizer products across 23 countries in Europe. This collaboration brings together Pfizer's scientific leadership with IQVIA's promotional expertise, market intelligence, and AI-supported technology to support long-term impact. We entered into a strategic long-term collaboration with Boehringer Ingelheim to transport the Global Commercial Intelligence Foundation. Boehringer selected IQVIA's data as a service TAS Plus platform as the core accelerator to harmonize and upgrade global commercial operations, enabling more scalable analytics and a single version of the truth across therapeutic areas and geography. This collaboration will support upcoming product …
A major emerging pharma/biotech is standardizing on IQVIA data platforms, expanding IQVIA's share of wallet.
“IQVIA was awarded a multi-year agreement to serve as the primary patient information and analytics partner across an EVP's full portfolio”
… with Boehringer Ingelheim to transport the Global Commercial Intelligence Foundation. Boehringer selected IQVIA's data as a service TAS Plus platform as the core accelerator to harmonize and upgrade global commercial operations, enabling more scalable analytics and a single version of the truth across therapeutic areas and geography. This collaboration will support upcoming product launches and market reporting across 59 countries. IQVIA was awarded a multi-year agreement to serve as the primary patient information and analytics partner across an EVP's full portfolio, including our data as a service platform. This partnership is designed to drive strong visibility into existing grants, step change improvements in analytics, insights, and pipeline assets, and more intelligent commercial and portfolio decisions. Let me now turn to R&D solutions. Our strategy in R&D is has been to leverage our AI solutions to optimize trial design and execution to reduce timelines for our clients. Of course, we've been doing this for years through protocol optimization, site identification, and operational risk mitigation. We're taking this to the next level with AI agents, which leads to …
IQVIA is leveraging NVIDIA's platform to launch its AI portal, indicating a deepening partnership that benefits both companies.
“A few weeks ago, we unveiled IQVIA.AI at NVIDIA's GTC conference.”
… As a quick reminder, IQVIA's AI solutions are built on our unparalleled proprietary data foundation. Based in class compliance with the privacy, regulatory, and integrity standards, healthcare-grade AI demands and are connected to our deep life sciences and healthcare expertise. We've been integrating AI into our operations and solutions at scale for nearly a decade. It's part of who we are and what we do. We already function as an AI native company in life sciences. A few weeks ago, we unveiled IQVIA.AI at NVIDIA's GTC conference. This is our agentic AI portal and marketplace, purpose-built for life sciences. It provides clients a single access point to their purchased IQVIA AI solutions, enabling centralized control with their internal user base, while also enabling visibility to a broader AI portfolio to support future solution adoption. Our deployment of highly specialized life science industry AI agents is progressing as planned. To date, we have 192 agents deployed in the field covering 64 use cases across both our commercial solutions and R&DF businesses. 19 of the top 20 pharma companies are already using IQVIA agents in some of their workflows, underscoring broad …